Baylx receives US FDA clearance of Covid-19 IND application for umbilical cord tissue mesenchymal stem cells product
This article was originally published here
Mesenchymal stem cells hold great promise to treat COVID-19 patients due to their potential in inhibiting the overactivated immune system and promoting the recovery of pulmonary and other
The post Baylx receives US FDA clearance of Covid-19 IND application for umbilical cord tissue mesenchymal stem cells product appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!